Download resource
PDF or document file
The DHA’s submission supports repealing the Therapeutic Products Act, arguing its broad SaMD regulation stifles innovation, increases costs, and limits digital health progress. CEO Ryl Jensen urges agile, risk-proportionate legislation that ensures safety while supporting industry growth and efficiency.